Sector
PharmaceuticalsOpen
₹55.43Prev. Close
₹53.67Turnover(Lac.)
₹2.29Day's High
₹57.7Day's Low
₹53.0352 Week's High
₹94.952 Week's Low
₹44.52Book Value
₹8.73Face Value
₹10Mkt Cap (₹ Cr.)
41.64P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -0.31 | -0.56 | 1.11 | 0.24 |
Net Worth | 7.11 | 6.86 | 8.53 | 7.66 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 40.13 | 25.17 | 37.54 | 29.01 |
yoy growth (%) | 59.4 | -32.93 | 29.39 | 14.73 |
Raw materials | -15.24 | -9.99 | -13.9 | -10.52 |
As % of sales | 37.99 | 39.68 | 37.03 | 36.25 |
Employee costs | -15.82 | -12.96 | -15.12 | -11.92 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 0.74 | -2.53 | 0.43 | 0.32 |
Depreciation | -0.27 | -0.17 | -0.24 | -0.18 |
Tax paid | 0.12 | 0.01 | -0.15 | -0.05 |
Working capital | 2 | -0.44 | 2.46 | -5.43 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.4 | -32.93 | 29.39 | 14.73 |
Op profit growth | -140.37 | -505.13 | 111.34 | 304.73 |
EBIT growth | -153.58 | -394.3 | 31.98 | 65.61 |
Net profit growth | -134.61 | -1,012.54 | 1.98 | -1,928.47 |
Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|
Gross Sales | 25.18 | 37.54 | 31.03 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 25.18 | 37.54 | 31.03 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.8 | 0.29 | 0.32 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Amrutbhai P Prajapati
Independent Director
Chhayaben Ashwinbhai Shah
Independent Director
Viplav Suryakantbhai Khamar
Managing Director & CEO
Aalap Prajapati
Independent Director
Surendra Kumar Sharma
Independent Director
Navinchandra Patel
Chairman & Wholetime Director
Natwarbhai P Prajapati
122/2 Ravi Estate,
Bileshwarpura Chhatral,
Gujarat - 382729
Tel: 91-079-6663 3706
Website: http://www.gtll.in; www.gujaratterce.com
Email: ho@gujaratterce.com
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market. Over its more than three-decade business journey, the Company developed an exte...
Read More
Reports by Gujarat Terce Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.